Review decision: November 2015

We checked this guideline and decided that it should be updated at this time. For details, see the update decision, decision matrix and the process for deciding if an update is needed. Details of the update will be available on the guidelines in development webpage in due course. This guideline will be checked again for update at its scheduled time point according to the methods described here

Next review date: 2017

This clinical guideline updates and replaces NICE guideline CG14 and CG41 (published in October 2006).

It offers evidence-based advice on the classification and care of people at risk of familial breast cancer. It also makes recommendations on genetic testing thresholds, surveillance and risk reduction and treatment strategies for people with a diagnosis of breast cancer and a family history of breast, ovarian or a related cancer.

These areas are not covered by NICE guideline CG80 (Breast cancer: early and locally advanced, published in February 2009).

This guideline was previously called familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer (CG164).

Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

  • National Institute for Health and Care Excellence (NICE) accreditation logo